Needle free: Erase wrinkles without injection
Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06
Conventional botulinum toxin products are in the form of syringes and are slow to perform their effect, PTx, one of Caregen's key products, has been developed into a cream and serum formulation and has a remarkable performance in 5 minutes.
Caregen is a Biotechnology company which manufactures and supplies functional cosmetics and cosmeceuticals like medical devices (fillers) based on the research and technology of Growth Factors and Peptides which acts just like Growth Factors. This technology-intensive enterprise develops and owns about 500 kinds of peptides with strong physiological activity and of these, 287 are registered as domestic and foreign patents.
Based on this technology, Caregen has achieved double-digit annual sales growth and industry-leading rate of operating profits. Dermaheal, Revofil and Prostrololane which are their own brands, are recognized abroad based on CE certification and they are exported to more than 130 countries which account for 90% of the total sales. In particular, in the M/S (market share) of the Russian and CIS filler markets, Caregen has been ranked 1st for several years.
Caregen is now preparing for a leap for greater growth. They have evolved from the small-scale framework of the sales structure of multi-product production system to a development of a product with high sales potential of blockbuster grade and is aiming to change the constitution from this year onwards.
One of their key products is PTx (Peptide Toxin), a peptide product that shows the mechanism of a botulinum toxin type C. PTx is a comprehensive product with Caregen’s know-how of Peptide development and it is the world's only cosmetic product with the mechanism of botulinum toxin. The existing botulinum toxin products are type A’s and they only cleave SNAP-25 of the snare complex within the neuron while PTx, a botulinum toxin type C product, is the world’s first product to show a strong mechanism of cleaving Syntaxin as well.
While the conventional botulinum toxin products are in the form of syringes and are slow to perform their effect, PTx has been developed into a cream and serum formulation and has a remarkable performance in 5 minutes. In addition, the advantage of PTx is that it exhibits variety of indications for typical botulinum toxins, including pain relief, hyperhidrosis, acne, sebum reduction and pore reduction, and Caregen has recently introduced a separate pain relief product called PTx Sports.
PTx sports is also a product of the cosmetics category, but has shown remarkable efficacy over medicines so it is effective to relieve from general muscle pains to chronic pains in 5 minutes. Since PTx sports is made of peptide components, it has additional advantages that it has no side effects on the body, has no smell or stickiness, and that it can be used easily.
Caregen is currently in deep discussions with many multinational companies in terms of licensing and distribution of PTx sports. Also, in preparation for the increase in demand, new investments for mass production are already under preparation and from the second half of next year, Caregen's production will more than triple.
In the meantime, the CEO of Caregen, Dr. Chung Yong Ji will present with the topic 'Topical Application of Botulinum Toxin Type C Peptide in Pharmaceutical and Aesthetic Applications' at 'Chpi Worldwide 2019' in Frankfurt on 11/5, 15:50 as the keynote speech for the seminar. You can also meet PTx from 11/5 - 11/7, Hall 4.2, 42C06 during the exhibition period.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...